Vaccinate
today
GARDASIL is recommended for
girls and women 9 to 26 years of age.
The Centers for Disease Control
and Prevention (CDC)
Advisory Committee on Immunization Practices (ACIP) recommends
HPV
vaccination
for girls and young women 9 to 26
years of age.†,3
According to the CDC, the most effective
time to vaccinate with any vaccine is before exposure.4
†ACIP recommends routine
vaccination of females 11 to 12 years of age. The vaccination
series
can be started as young as 9 years. Vaccination is also recommended
for 13- to
26-year-old females not previously vaccinated.3
‡In an analysis of 1,552 adolescents
and young adults, the subset (n=1,014) featured in this chart
reported having
engaged in sexual intercourse.5
>Learn
how to help protect 9- to 15-year-old girls. It’s
not too late to protect patients exposed to HPV
In clinical trials for GARDASIL§:
§Worldwide
clinical analyses of more than 20,000 young women 16 to 26
years of age with a lifetime history of <5 sexual
partners.
GARDASIL is a vaccine indicated in girls and women 9 to 26
years of age for the prevention of cervical cancer, precancerous
or dysplastic lesions, and genital warts caused by HPV Types
6, 11, 16, and 18.
Select safety information
GARDASIL is contraindicated in individuals who are hypersensitive to the active
substances or to any of the excipients of the vaccine.
Vaccination with GARDASIL may not result in protection in all vaccine recipients.
GARDASIL is not intended to be used for treatment of active genital warts;
cervical cancer; cervical intraepithelial neoplasia, vulvar intraepithelial
neoplasia, or vaginal intraepithelial neoplasia.
GARDASIL does not substitute for routine cervical cancer screening, and women
who receive GARDASIL should continue to undergo screening per standard of care.
GARDASIL has not been shown to protect against diseases due to non-vaccine
HPV types.
The duration of protection of GARDASIL is unknown at present. GARDASIL will
not protect against diseases that are not caused by HPV.
The vaccine-related adverse experiences that were observed among recipients
of GARDASIL at a frequency of at least 1.0% and greater than placebo were pain,
swelling, erythema, fever, nausea, pruritus, and dizziness. In addition, common
postmarketing reports include vomiting and syncope.
As with all injectable vaccines, appropriate medical treatment should always
be readily available in case of rare anaphylactic reactions following the administration
of the vaccine.
A complete vaccination regimen of GARDASIL consists of a 3-dose schedule.
See Safety and
Tolerability and Dosage
and Administration.
Before administering GARDASIL, please read the Prescribing
Information and Patient
Product Information.
GARDASIL is a registered trademark of Merck & Co., Inc.
|
